Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Feb 19;10(2):441.
doi: 10.3390/cells10020441.

Switching to an Infliximab Biosimilar Was Safe and Effective in Dutch Sarcoidosis Patients

Bas J M Peters  1 , Anish Bhatoe  1 , Adriane D M Vorselaars  2 , Marcel Veltkamp  2   3
Affiliations
Review

Switching to an Infliximab Biosimilar Was Safe and Effective in Dutch Sarcoidosis Patients

Bas J M Peters et al. Cells. .

Abstract

The effect of switching from originator infliximab to biosimilar infliximab in patients with sarcoidosis is unknown. The objective of this study is to investigate the effect of switching from Remicade® or Inflectra® to Flixabi® in patients with severe refractory sarcoidosis. This single center retrospective cohort study was performed at St Antonius Hospital Nieuwegein, The Netherlands. All patients diagnosed with severe refractory sarcoidosis receiving Remicade® or Inflectra® switched to Flixabi®. The primary outcome was infliximab discontinuation within 6 months of switching. Secondary endpoints included adverse events and loss of clinical, functional, or inflammatory response. Out of 86 patients who switched to Flixabi®, 79 patients had complete data. None of the 79 patients discontinued infliximab during the first 6 months after switching. Five patients reported an adverse event related to Flixabi® treatment. We found no change from baseline in FVC, FEV1, DLCOc, 6MWT, and infliximab trough levels 26 weeks after switching. An improvement in physical functioning of 7.3 ± 13.4 points (p = 0.002) with RAND/SF36 and in biomarker sIL-2R (-475.58 ± 1452.39; p = 0.005) was observed. Switching from originator infliximab Remicade® or biosimilar infliximab Inflectra® to biosimilar infliximab Flixabi® did not result in treatment discontinuation or loss of clinical/functional/inflammatory remission.

Keywords: TNF-α inhibitor; biosimilar; infliximab; sarcoidosis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Valeyre D., Prasse A., Nunes H., Uzunhan Y., Brillet P.-Y., Müller-Quernheim J. Sarcoidosis. Lancet. 2014;383:1155–1167. doi: 10.1016/S0140-6736(13)60680-7. - DOI - PubMed
    1. Wirnsberger R.M., de Vries J., Wouters E.F., Drent M. Clinical presentation of sarcoidosis in The Netherlands an epidemiological study. Neth. J. Med. 1998;53:53–60. doi: 10.1016/S0300-2977(98)00058-8. - DOI - PubMed
    1. Culver D.A., Judson M.A. New advances in the management of pulmonary sarcoidosis. BMJ. 2019:l5553. doi: 10.1136/bmj.l5553. - DOI - PubMed
    1. Baughman R.P., Drent M., Kavuru M., Judson M.A., Costabel U., du Bois R., Albera C., Brutsche M., Davis G., Donohue J.F., et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am. J. Respir. Crit. Care Med. 2006;174:795–802. doi: 10.1164/rccm.200603-402OC. - DOI - PubMed
    1. Baughman R.P., Lower E.E. Infliximab for refractory sarcoidosis. Sarcoidosis Vasc. Diffus. Lung Dis. Off. J. WASOG. 2001;18:70–74. - PubMed

LinkOut - more resources